Immediate Impact

65 standout
Sub-graph 1 of 22

Citing Papers

Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association
2025 Standout
Pharmacological treatment for metabolic dysfunction–associated steatotic liver disease and related disorders: Current and emerging therapeutic options
2025 Standout
2 intermediate papers

Works of Yusuf Kayar being referenced

Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease
2015

Author Peers

Author Last Decade Papers Cites
Yusuf Kayar 172 79 180 86 68 457
Endrit Shahini 116 73 208 57 48 462
Adrian Boicean 163 37 114 156 58 463
Abdullah Özgür Yeniova 195 136 196 36 42 495
Selim Gökçe 162 65 135 28 30 424
Daniel Vasile Balaban 249 185 153 39 65 504
Maşallah Baran 230 133 98 55 68 485
Alpaslan Tanoğlu 171 22 181 82 95 487
Prasun K. Jalal 86 20 163 62 55 448
Eugen Dumitru 140 39 137 76 58 408
Dragan Popović 139 34 202 52 44 432

All Works

Loading papers...

Rankless by CCL
2026